180 related articles for article (PubMed ID: 28349025)
1. Optimization of the Expression of DT386-BR2 Fusion Protein in
Shafiee F; Rabbani M; Jahanian-Najafabadi A
Adv Biomed Res; 2017; 6():22. PubMed ID: 28349025
[TBL] [Abstract][Full Text] [Related]
2. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
3. Expression and purification of truncated diphtheria toxin, DT386, in
Shafiee F; Rabbani M; Behdani M; Jahanian-Najafabadi A
Res Pharm Sci; 2016 Oct; 11(5):428-434. PubMed ID: 27920826
[TBL] [Abstract][Full Text] [Related]
4. Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein.
Pourhadi M; Jamalzade F; Jahanian-Najafabadi A; Shafiee F
Res Pharm Sci; 2019 Aug; 14(4):320-328. PubMed ID: 31516508
[TBL] [Abstract][Full Text] [Related]
5. Expression and purification of soluble and functional fusion protein DAB
Zarkar N; Nasiri Khalili MA; Khodadadi S; Zeinoddini M; Ahmadpour F
Biotechnol Appl Biochem; 2020 Mar; 67(2):206-212. PubMed ID: 31600001
[TBL] [Abstract][Full Text] [Related]
6. High-level Expression of Tetanus Toxin Fragment C in Escherichia coli.
Aghaiypour K; Teymourpour R
Arch Razi Inst; 2018 Dec; 73(1):27-38. PubMed ID: 30256036
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Five Escherichia coli Strains to Achieve the Maximum Yield of a Recombinant Immunotoxin Consisting of an Antibody against VEGF Conjugated with MAP30 Toxin in a Benchtop Bioreactor.
Zarei M; Morowvat MH
Recent Pat Biotechnol; 2024; 18(1):52-62. PubMed ID: 38205774
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of recombinant beta toxin of Clostridium perfringens type B using a commercially available Escherichia coli strain.
Bakhshi F; Pilehchian Langroudi R; Eimani BG
Onderstepoort J Vet Res; 2016 Jun; 83(1):a1136. PubMed ID: 27380656
[TBL] [Abstract][Full Text] [Related]
9. Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage.
Larentis AL; Argondizzo AP; Esteves Gdos S; Jessouron E; Galler R; Medeiros MA
Protein Expr Purif; 2011 Jul; 78(1):38-47. PubMed ID: 21362478
[TBL] [Abstract][Full Text] [Related]
10. Efficient expression of EpEX in the cytoplasm of
Rasooli F; Hashemi A
Res Pharm Sci; 2019 Dec; 14(6):554-565. PubMed ID: 32038735
[TBL] [Abstract][Full Text] [Related]
11. Expression of Mastoparan B, a Venom Peptide, Via Escherichia coli C43 (DE3) Coupled with an Artificial Oil Body-Cyanogen Bromide Technology Platform.
Hsieh SK; Yu YJ; Tang NY; Lin JR; Jinn TR
Protein Pept Lett; 2017; 24(11):1021-1029. PubMed ID: 28741464
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of solubility in Escherichia coli and purification of an aminotransferase from Sphingopyxis sp. MTA144 for deamination of hydrolyzed fumonisin B(1).
Hartinger D; Heinl S; Schwartz HE; Grabherr R; Schatzmayr G; Haltrich D; Moll WD
Microb Cell Fact; 2010 Aug; 9():62. PubMed ID: 20718948
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Three Escherichia coli Strains in Recombinant Production of Reteplase.
Fathi-Roudsari M; Akhavian-Tehrani A; Maghsoudi N
Avicenna J Med Biotechnol; 2016; 8(1):16-22. PubMed ID: 26855731
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the heterologous expression and purification of Plasmodium falciparum generative cell specific 1 in Escherichia coli.
Ayoub Meigouni M; Abouie Mehrizi A; Fazaeli A; Zakeri S; Djadid ND
Protein Expr Purif; 2022 Oct; 198():106126. PubMed ID: 35661702
[TBL] [Abstract][Full Text] [Related]
15. Optimization of culture conditions for
Kusuma SAF; Parwati I; Rostinawati T; Yusuf M; Fadhlillah M; Ahyudanari RR; Rukayadi Y; Subroto T
Heliyon; 2019 Nov; 5(11):e02741. PubMed ID: 31844694
[TBL] [Abstract][Full Text] [Related]
16. Enhanced production of human mini-proinsulin in fed-batch cultures at high cell density of Escherichia coli BL21(DE3)[pET-3aT2M2].
Shin CS; Hong MS; Bae CS; Lee J
Biotechnol Prog; 1997; 13(3):249-57. PubMed ID: 9190075
[TBL] [Abstract][Full Text] [Related]
17. On the expression of recombinant Cas9 protein in E. coli BL21(DE3) and BL21(DE3) Rosetta strains.
Carmignotto GP; Azzoni AR
J Biotechnol; 2019 Dec; 306():62-70. PubMed ID: 31545973
[TBL] [Abstract][Full Text] [Related]
18. Expression of Recombinant pET22b-LysK-Cysteine/Histidine-Dependent Amidohydrolase/Peptidase Bacteriophage Therapeutic Protein in Escherichia coli BL21 (DE3).
Kashani HH; Moniri R
Osong Public Health Res Perspect; 2015 Aug; 6(4):256-60. PubMed ID: 26473093
[TBL] [Abstract][Full Text] [Related]
19. Use of modified BL21(DE3) Escherichia coli cells for high-level expression of recombinant peanut allergens affected by poor codon usage.
Kleber-Janke T; Becker WM
Protein Expr Purif; 2000 Aug; 19(3):419-24. PubMed ID: 10910733
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Secreted Recombinant Human Epidermal Growth Factor Production Using Pectate Lyase B from
Sriwidodo S; Subroto T; Maksum IP; Wathoni N; Rostinawati T; Ulya H; Putri IU
J Pharm Bioallied Sci; 2019 Dec; 11(Suppl 4):S562-S566. PubMed ID: 32148364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
